Kiniksa Pharmaceuticals International (KNSA) Expected to Post Quarterly Earnings on Tuesday

Key Points

• Kiniksa is expected to report Q3 2026 results before market open on October 27. Analysts forecast earnings of $0.3722 per share on $260.21 million in revenue; the earnings call is scheduled for 8:30 a.m. ET.
• The company’s previous quarter met EPS expectations at $0.30 and exceeded revenue estimates, reporting $243.60 million versus the $226.49 million consensus.
• Analyst sentiment remains positive, with eight Buy ratings and one Hold rating, a “Moderate Buy” consensus, and an average price target of $93.14. KNSA recently traded near its 52-week high, while insiders own approximately 51.98% of shares.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.3722 per share and revenue of $260.21 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting analysts' consensus estimates of $0.30. The business had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, analysts expect Kiniksa Pharmaceuticals International to post $1.37 EPS for the current fiscal year and $2.07 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $79.48 on Tuesday. The stock has a market cap of $6.20 billion, a P/E ratio of 81.94 and a beta of 0.04. Kiniksa Pharmaceuticals International has a one year low of $35.20 and a one year high of $82.98. The stock has a fifty day moving average price of $77.93 and a 200 day moving average price of $64.29.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of the company's stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the firm's stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director directly owned 11,672 shares of the company's stock, valued at approximately $950,450.96. The trade was a 23.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 51.98% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on KNSA shares. Citigroup increased their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 12th. Wells Fargo & Company assumed coverage on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, September 30th. They issued an "overweight" rating and a $87.00 price target for the company. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. Finally, Weiss Ratings raised Kiniksa Pharmaceuticals International from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $93.14.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.